RT info:eu-repo/semantics/article
T1 A mathematical model to simulate the biological action of Infliximab on TNF-α in patients with Inflammatory Bowel Disease: the critical role of drug clearance
A1 Portillo de la Fuente, Ana María
A1 Prado Santos, Ángel de
A1 Soares, Ana J.
K1 Modelos matemáticos
K1 Biomedicina
K1 Enfermedad inflamatoria intestinal
K1 Enfermedad inflamatoria intestinal
K1 TNF-α
K1 Infliximab
K1 Terapia biológica
K1 Eliminación de fármacos
K1 Modelización matemática
K1 12 Matemáticas
K1 2404 Biomatemáticas
AB Inflammatory bowel disease (IBD), including Crohn s disease (CD) and ulcerative colitis (UC), is characterized by chronic intestinal inflammation driven by elevated tumor necrosis factor-alpha (TNF-α). Infliximab, an anti-TNF-α monoclonal antibody, is widely used in the treatment of inflammatory bowel disease but shows variable effectiveness due to interindividual pharmacokinetic diversity. We develop a low-dimensional mathematical model of ordinary differential equations to describe TNF-α dynamics, its interactions with receptors and infliximab, and the influence of drug clearance on treatment outcomes in CD and UC. This model is combined with a pharmacokinetic framework that enables the estimation of the infliximab clearance coefficient, which can then be used to guide dosage adjustments in the treatment. The model balances biological realism with analytical tractability, enabling rigorous mathematical analysis and numerical simulations. The parameters are adapted for CD and UC. The study investigates how drug clearance influences treatment efficacy, initially using constant clearance values and later incorporating values that vary with the level of inflammation. Simulations are performed across a range of clearance rates and dosing regimens, providing detailed insights into infliximab and TNF-α dynamics, as well as therapeutic drug monitoring parameters. Our results highlight the critical role of clearance and therapeutic drug monitoring in optimizing infliximab therapy. This approach offers valuable insights to support personalized treatment strategies in IBD.
PB Springer Nature
SN 0092-8240
YR 2026
FD 2026
LK https://uvadoc.uva.es/handle/10324/82745
UL https://uvadoc.uva.es/handle/10324/82745
LA eng
NO Bulletin of Mathematical Biology, 2026, vol. 88, n. 3.
NO Producción Científica
DS UVaDOC
RD 13-feb-2026